Skip to main content
Legal (Not So) Merry-Go-Round of Alendronate Atypical Fractures

Dr. Gregory Curfman, MD writes on the chronological le

Dr. John Cush RheumNow

2 years 3 months ago
Legal (Not So) Merry-Go-Round of Alendronate Atypical Fractures Dr. Gregory Curfman, MD writes on the chronological legal progress of a lawsuit stemming from rare instances of atypical femoral fractures associated with bisphosphonate (alendronate) use. https://t.co/6Ipvw7tcKr https://t.co/VNrMg88AsH
Antacids can Diminish Bone Density

Proton pump inhibitors (PPIs), a specific class of antacid drugs, are among the mos

Dr. John Cush RheumNow

2 years 3 months ago
Antacids can Diminish Bone Density Proton pump inhibitors (PPIs), a specific class of antacid drugs, are among the most widely used medications of all. They are frequently prescribed to many groups of patients, including those with rheumatism. https://t.co/Ii8DlDgBx7 https://t.co/cWN7v7PiIf
Retrospective 170 RA pts Rx w/ IFX, ADA, & CZP shows CZP levels didnt differ w/ low or HI RF; but high basel RF link

Dr. John Cush RheumNow

2 years 3 months ago
Retrospective 170 RA pts Rx w/ IFX, ADA, & CZP shows CZP levels didnt differ w/ low or HI RF; but high basel RF linked to lower IFX & ADA drug levels, W/O DAS28 differences, but more IFX/ADA D/C w/ Hi baseline RF levels (80% vs. 75% vs. 33% CZP, p=0.002) https://t.co/OVUcKAgJ5a https://t.co/kzWd8jHXs3
A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis (LN) demonstrates both the benefits and harms to early glucocorticoid (GC) regimens on lupus outcomes. 
Consensus Statements on Vitamin D

The “Controversies in Vitamin D” International Conference has published their pr

Dr. John Cush RheumNow

2 years 3 months ago
Consensus Statements on Vitamin D The “Controversies in Vitamin D” International Conference has published their proceedings on vitamin D metabolism, assessment, actions, and supplementation. https://t.co/QGXbJdJpAC https://t.co/N1UkTi6u8C
Small-molecule Drugs to Treat Systemic Lupus Erythematosus

A metanalysis of randomized controlled trials (RCTs) on tre

Dr. John Cush RheumNow

2 years 3 months ago
Small-molecule Drugs to Treat Systemic Lupus Erythematosus A metanalysis of randomized controlled trials (RCTs) on treatments of systemic lupus erythematosus (SLE), confirm the efficacy of several targeted small-molecule drugs. https://t.co/O3Y3KBngau https://t.co/wiB1EMtMFK
Interferons and Lupus Subsets

In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights

Dr. John Cush RheumNow

2 years 3 months ago
Interferons and Lupus Subsets In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights as to the relationship between interferons and lupus, which affects up to 1.5 million Americans. https://t.co/Eo8q3IGPb7 https://t.co/gVyHJwZFwc
Risk Factors for Hydroxychloroquine Retinopathy

A long-term hydroxychloroquine users study found that 2.7% developed r

Dr. John Cush RheumNow

2 years 3 months ago
Risk Factors for Hydroxychloroquine Retinopathy A long-term hydroxychloroquine users study found that 2.7% developed retinopathy, and identified risk factors as increasing age, female sex, chronic kidney disease stage 3+ and tamoxifen use. https://t.co/iC7eh0XLzE https://t.co/gDaWi4kt1h
Metanalysis of 26 reports and 195 juvenile Dermatomyositis pts (age 4.9 yrs) treated w/ JAK inhib (tofa, rux, & bari

Dr. John Cush RheumNow

2 years 3 months ago
Metanalysis of 26 reports and 195 juvenile Dermatomyositis pts (age 4.9 yrs) treated w/ JAK inhib (tofa, rux, & bari); Good improvement in 90%, 69% & 93%, respectively. JAK indication refractory skin dz (35%) or muscle involvement (29%). TIME FOR RCTs!! https://t.co/Vtm2n9BWV1 https://t.co/1bXZokW1AO
Review article of Interstitial Lung Dz Assoc w/ Systemic Sclerosis. SSc-ILD prevalence ranges 25-95%; ILD is a main caus

Dr. John Cush RheumNow

2 years 3 months ago
Review article of Interstitial Lung Dz Assoc w/ Systemic Sclerosis. SSc-ILD prevalence ranges 25-95%; ILD is a main cause of morbidity and mortality, contributing to 35% of deaths https://t.co/8mMFbDu4gi https://t.co/nQ4GfNcMWt
Alot of murky "research" on Platelet-rich plasma (PRP). This RCT of120 pts having anterior cruciate ligament reconstruct

Dr. John Cush RheumNow

2 years 3 months ago
Alot of murky "research" on Platelet-rich plasma (PRP). This RCT of120 pts having anterior cruciate ligament reconstruction (half randomized to PRP) shows no PRP benefit, no significant improvement of knee symptoms & function post ACLR https://t.co/AwkCAq1QFb https://t.co/YP0hJd7soc
Retrospective cohort study compared 5825 #AS pts vs 28,356 matched controls; showed an increased risk of pulmonary embol

Dr. John Cush RheumNow

2 years 3 months ago
Retrospective cohort study compared 5825 #AS pts vs 28,356 matched controls; showed an increased risk of pulmonary embolism w/ AS; not present pre-Dx ((0.4% vs 0.2%), but incr post-AS Dx (PE IR 11.6 vs 6.8/10KPY: adj HR 1.70;; p<0.001) https://t.co/wSkAMozvnL https://t.co/5Q470QkAxe
K Kuhn et al: Altered tryptophan catabolism by microbiome may contribute to inflammatory arthritis. Tryptophan increases

Dr. John Cush RheumNow

2 years 3 months ago
K Kuhn et al: Altered tryptophan catabolism by microbiome may contribute to inflammatory arthritis. Tryptophan increases indole leading to ncreases in serum IL-6, TNF, and IL-1β; splenic RORγt+CD4+ T cells, & IL-23 and IL-17 production https://t.co/i9le12QZm2 https://t.co/akeXxWnQ9o
×